Klebsiella pneumoniae is a rod shaped type of bacteria commonly found in the normal flora of the mouth, skin, and intestines.
K. pneumoniae can in turn cause an infection called klebsiella pneumonia. This can provoke lung inflammation and cell death that may produce a thick, bloody, mucoid sputum. This often happens after the bacteria migrate from their normal place of resting to the lower respiratory tract. (For more on this see the questions below)
The KPC superbug arises when the Klebsiella bacteria become resistant to the carbapenem drugs often used to treat them. These drug resistant bacteria are called Carbapenemases. They are active in other bacteria beside Klebsiella and this resistance group are sometimes referred to as Carbapenem Resistant En (CRE)
Different types of KPC exist around the world and are most often seen in hospital patients with compromised immune systems and significant exposure to hospital infections. They have spread around the USA in the last 10 years and often have a foothold in long term care facilities.
They have gained media attention since September 2012 because of the interest in the battle that the National Insitute of Health experienced in uprooting the infection from their state of the art facility and the many deaths that have occurred from one single outbreak. KPC and CRE are considered to be among the most potent threats to public health in the world at this time. They threaten to turn formerly treatable infections into life ending challenges.
See our KPC superbug guide below
- KPC News – Daily Updates
- How is the KPC superbug treated
- What are KPC superbug symptoms
- What is Klebsiella Pneumonia?
- What is the KPC superbug?
The latest news on carbapenemases is below. You can sign up for our weekday newsletter here
- First report of OXA-72 producing Acinetobacter baumannii in Romania.
- Carbapenem-resistant Acinetobacter baumannii mediastinitis after aortic graft implantation successfully treated by adjunctive gentian violet irrigation and antibiotic combination therapy.
- Effects of implementation of an online comprehensive antimicrobial-stewardship program in ICUs: A longitudinal study.
- Precision Healthcare Milestone Reached as Food and Drug Administration Clears New Multi-Marker Medical
- Pfizer and Astrazeneca
- AstraZeneca To Sell Small Molecule Antibiotics Business To Pfizer - Clinical Leader
- A Flow Cytometric and Computational Approaches to Carbapenems Affinity to the Different Types of Carbapenemases.
- Molecular Characterization of Invasive Carbapenem-Resistant Acinetobacter baumannii from a Tertiary Care Hospital in South India.
- Reduction of Hospital Contamination Using Automatic UV
- The role of doxycycline in the therapy of multidrug-resistant E. coli - an in vitro study.
- A Child With Septic Shock and Purpura.
- A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.
- High prevalence of the PER-1 gene among carbapenem-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia. - PubMed - NCBI
- Carbapenem Resistance in Acinetobacter baumannii and Other Acinetobacter spp. Causing Neonatal Sepsis: Focus on NDM-1 and Its Linkage to ISAba125.
- A pharmacokinetic–pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure